Advances in competing endogenous Rnas in pancreatic cancer

doi:10.3877/cma.j.issn.1674-3946.2023.02.025

Abstract

Abstract:

Pancreatic cancer is a highly malignant digestive system tumor，and pancreatic ductal adenocarcinoma（PDAC）is the most common pathological type of pancreatic cancer. At present，the biological indicators for the diagnosis of pancreatic cancer are still limited，and the specificity needs to be further improved. Pancreatic cancer is a common disease with occult onset，rapid progression and uncertain mechanism. In recent years，there have been a lot of molecular studies on the biological function of pancreatic cancer，and the competitive endogenous RNA（ceRNA）hypothesis is one of the most studied hypotheses. Studies have shown that long non-coding Rnas（lncrnas），circrnas（circrnas）and pseudogenes can be used as CERnas to participate in the construction of ceRNA networks and affect the biological function of pancreatic cancer cells through corresponding pathways. In recent years，a large number of studies have found that ceRNA plays an important role in the generation，development and resistance to chemotherapy drugs of pancreatic cancer. The purpose of this paper is to systematically summarize and analyze the effects of ceRNA on biological function of pancreatic cancer cells in recent years，and to provide reference for future research.

Key words: Pancreatic Neoplasms, Competing Endogenous RNA, Long Non-Coding RNA, Micro RNA, Circular RNA

Bo Zhang, Wei Han, Shaolong Hao, Zeqian Li, Zhili Ji. Advances in competing endogenous Rnas in pancreatic cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 213-216.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2023.02.025

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2023/V17/I02/213

Figures/Tables 2

References 31

[1]	赵建国，廖泉，赵玉沛. 胰腺癌分子标志物研究进展［J/CD］. 中华普外科手术学杂志（电子版），2013，7（03）：224-226.
[2]	Salmena L，Poliseno L，Tay Y，et al. A ceRNA Hypothesis：The Rosetta Stone of a Hidden RNA Language？［J］. Cell，2011，146（3）：353-358.
[3]	Tay Y，Rinn J，Pandolfi P P. The multilayered complexity of ceRNA crosstalk and competition［J］. Nature，2014，505（7483）：344-352.
[4]	Necsulea A，Soumillon M，Warnefors M，et al. The evolution of lncRNA repertoires and expression patterns in tetrapods［J］. Nature，2014，505（7485）：635-640.
[5]	Zhang H D，Jiang L H，Sun D W，et al. CircRNA：a novel type of biomarker for cancer［J］. Breast Cancer，2018，25（1）：1-7.
[6]	Lou W，Ding B，Fu P. Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer［J］. Front Cell Dev Biol，2020，8：85.
[7]	Liu P，Pan Y，Wang D，et al. Long non-coding RNA XIST promotes cell proliferation of pancreatic cancer through miR-137 and Notch1 pathway［J］. Eur Rev Med Pharmacol Sci，2020，24（23）：12161-12170.
[8]	Han Q，Li J，Xiong J，et al. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression［J］. J Exp Clin Cancer Res，2020，39（1）：151.
[9]	Guo Z，Wang X，Yang Y，et al. Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer［J］. Molecular Therapy - Nucleic Acids，2020，22：179-195.
[10]	Xiong G，Liu C，Yang G，et al. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer［J］. Journal of Hematology & Oncology，2019，12（1）：97.
[11]	Lei S，He Z，Chen T，et al. Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway［J］. J Exp Clin Cancer Res，2019，38（1）：470.
[12]	Liu Y，Wang J，Dong L，et al. Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gemcitabine（GEM）Resistance By Sponging Hsa-miR-214-3p To Target HDGF［J］. Onco Targets Ther，2019，12：8207-8216.
[13]	Sun Y，Wang P，Yang W，et al. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis［J］. Cancer Biology & Therapy，2019，20（6）：729-739.
[14]	Hua Y，Zhu Y，Xie G，et al. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1［J］. Aging（Albany NY），2019，11（20）：8860-8878.
[15]	Ling S，He Y，Li X，et al. CircRHOT1 mediated cell proliferation，apoptosis and invasion of pancreatic cancer cells by sponging miR‐125a‐3p［J］. Journal of cellular and molecular medicine，2020，24（17）：9881-9889.
[16]	Han X，Fang Y，Chen P，et al. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis［J］. Cell Cycle，2021，20（4）：369-382.
[17]	Wong CH，Lou UK，Li Y，et al. CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942［J］. Cancer Res，2020，80（11）：2138-2149.
[18]	Shen P，Yang T，Chen Q，et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing［J］. Mol Cancer，2021，20（1）：51.
[19]	Kong Y，Li Y，Luo Y，et al. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer［J］. Mol Cancer，2020，19（1）：82.
[20]	Han X，Fang Y，Chen P，et al. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis［J］. Cell Cycle，2021，20（4）：369-382.
[21]	Yu S，Wang M，Zhang H，et al. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis［J］. Genes（Basel），2021，12（11）：1701.
[22]	Ma HW，Xie M，Sun M，et al. The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression［J］. Oncotarget，2017，8（32）：52211-52224.
[23]	Huang W，Li N，Hu J，et al. Inhibitory effect of RNA-mediated knockdown of zinc finger protein 91 pseudogene on pancreatic cancer cell growth and invasion［J］. Oncol Lett，2016，12（2）：1343-1348.
[24]	Lian Y，Yang J，Lian Y，et al. DUXAP8，a pseudogene derived lncRNA，promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2［J］. Cancer Commun（Lond），2018，38（1）：64.
[25]	Abue M，Yokoyama M，Shibuya R，et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer［J］. Int J Oncol，2015，46（2）：539-547.
[26]	Cao R，Wang K，Long M，et al. miR-3613-5p enhances the metastasis of pancreatic cancer by targeting CDK6［J］. Cell Cycle，2020，19（22）：3086-3095.
[27]	Xu B，Liu J，Xiang X，et al. Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance［J］. Cancer Biother Radiopharm，2018，33（9）：373-379.
[28]	Yu Y，Tong Y，Zhong A，et al. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer［J］. Medicine（Baltimore），2020，99（52）：e23863.
[29]	Guz M，Jeleniewicz W，Cybulski M，et al. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis［J］. Biomed Rep，2021，14（1）：10.
[30]	Meng Q，Liang C，Hua J，et al. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance：functional validation and clinical significance［J］. Theranostics，2020，10（9）：3967-3979.
[31]	Zibitt M M S，Hartford CCR，Lal A. Interrogating lncRNA functions via CRISPR/Cas systems［J］. RNA Biol，2021，18（12）：2097-2106.

LncRNA	微小RNA	下游靶基因	效应
XIST	MiR-137	NOTCH1	促进胰腺癌细胞增殖
00514	MiR-28-5p	Rap1b	加速胰腺癌的进展
UCA1	MiR-96-5p	AMOTL2	促进胰腺癌血管生成
00976	Mir-137	OTUD7B	加速胰腺癌的进展
GSTM3TV2	LET-7	GLO1、KLK6、LAT2等	促进胰腺癌细胞对吉西他滨的耐药
DLEU2L	MiR-210-3p	BRCA2	抑制胰腺癌细胞对吉西他滨的耐药
HCP5	MiR-214-3p	HDGF	促进胰腺癌细胞对吉西他滨的耐药
MSC-AS1^[13]	MiR-29b-3p	CDK14	与胰腺癌预后较差相关
SBF2-AS1^[14]	MiR-142-3p	TWF1	促进胰腺癌细胞对吉西他滨的耐药

LncRNA	微小RNA	下游靶基因	效应
XIST	MiR-137	NOTCH1	促进胰腺癌细胞增殖
00514	MiR-28-5p	Rap1b	加速胰腺癌的进展
UCA1	MiR-96-5p	AMOTL2	促进胰腺癌血管生成
00976	Mir-137	OTUD7B	加速胰腺癌的进展
GSTM3TV2	LET-7	GLO1、KLK6、LAT2等	促进胰腺癌细胞对吉西他滨的耐药
DLEU2L	MiR-210-3p	BRCA2	抑制胰腺癌细胞对吉西他滨的耐药
HCP5	MiR-214-3p	HDGF	促进胰腺癌细胞对吉西他滨的耐药
MSC-AS1^[13]	MiR-29b-3p	CDK14	与胰腺癌预后较差相关
SBF2-AS1^[14]	MiR-142-3p	TWF1	促进胰腺癌细胞对吉西他滨的耐药

CircRNA	微小RNA	下游靶基因	效应
0071036	MiR-489	不详	促进胰腺癌细胞的生长
FOXK2	MiR-942	ANK1、GDNF	促进胰腺癌细胞的生长、迁移和侵袭
NEIL3	MiR-432-5p	GLI1	促进胰腺癌细胞上皮向间充质转化
NFIB1	MiR-486-5p	PIK3R1	抑制胰腺癌组织淋巴管生成
RHOT1	MiR-125a-3p	E2F3	促进胰腺癌细胞的增殖和侵袭

CircRNA	微小RNA	下游靶基因	效应
0071036	MiR-489	不详	促进胰腺癌细胞的生长
FOXK2	MiR-942	ANK1、GDNF	促进胰腺癌细胞的生长、迁移和侵袭
NEIL3	MiR-432-5p	GLI1	促进胰腺癌细胞上皮向间充质转化
NFIB1	MiR-486-5p	PIK3R1	抑制胰腺癌组织淋巴管生成
RHOT1	MiR-125a-3p	E2F3	促进胰腺癌细胞的增殖和侵袭

Please choose a citation manager

Content to export